BofA analyst Ashwani Verma raised the firm’s price target on Intra-Cellular to $63 from $62 and keeps a Buy rating on the shares after the company reported Phase 3 results from its Caplyta mixed features of depression study. The study showed a strong treatment effect relative to the placebo control and there were no anomalous side effects flagged, said the firm, which sees the data derisking a mixed features indication.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular price target raised to $74 from $66 at Mizuho
- Intra-Cellular price target raised to $98 from $93 at Canaccord
- Needham says positive move in Intra-Cellular stock makes sense
- ITCI Gains on Promising Results in Depression Treatment
- Intra-Cellular: Study 403 of lumateperone met primary endpoint for MDD
